Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACACB | O00763 | 1/20 | 0.47 |
| ▸ | LTA4H | P09960 | 1/20 | 0.47 |
| ▸ | PPARA | Q07869 | 3/20 | 0.42 |
| ▸ | PPARG | P37231 | 1/20 | 0.42 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.39 |
| ▸ | PPARD | Q03181 | 2/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | CA12 | O43570 | 1/20 | 0.39 |
| ▸ | CA1 | P00915 | 1/20 | 0.39 |
| ▸ | CA2 | P00918 | 1/20 | 0.39 |
| ▸ | CA7 | P43166 | 1/20 | 0.39 |
| ▸ | CA9 | Q16790 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5796 | 0.91 | MAOB (0.46) | FFAR1 | |
| SCHEMBL6072 | 0.85 | LMNA (0.52) | ACACBPPARAPPARGALDH1A1LMNA | |
| SCHEMBL11899992 | 0.84 | PARP10 (0.48) | PPARAPPARGFFAR1PPARDCA12 | |
| SCHEMBL11898792 | 0.80 | ADAMTS4 (0.48) | ACACBALDH1A1SMN1; SMN2 | |
| SCHEMBL12050 | 0.78 | ACACB (0.43) | ACACBLTA4HPPARAPPARGFFAR1 | |
| SCHEMBL6011 | 0.78 | CA12 (0.46) | ACACBCA12CA1CA2CA7 | |
| SCHEMBL6157 | 0.77 | PARP10 (0.43) | FFAR1CA12CA1CA2CA7 | |
| SCHEMBL6211 | 0.77 | MAOB (0.57) | PPARAPPARGFFAR1 | |
| SCHEMBL11592 | 0.76 | ACACB (0.39) | ACACB | |
| SCHEMBL12984880 | 0.75 | CYP3A4 (0.39) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140364398-A1 | C-Linked Hydroxamic Acid Derivatives Useful As Antibacterial Agents | PFIZER INC. (US) | 2014-12-11 | — | — | US | disclosed |
| US-8853258-B2 | C-linked hydroxamic acid derivatives useful as antibacterial agents | PFIZER INC. (US) | 2014-10-07 | — | — | US | disclosed |
| EP-2488489-A2 | C-LINKED HYDROXAMIC ACID DERIVATIVES USEFUL AS ANTIBACTERIAL AGENTS | Pfizer Inc. (US) | 2012-08-22 | — | — | EP | disclosed |
| US-20120202777-A1 | C-Linked Hydroxamic Acid Derivatives Useful As Antibacterial Agents | BROWN MATTHEW FRANK (US) | 2012-08-09 | — | — | US | disclosed |
| WO-2011045703-A2 | C-LINKED HYDROXAMIC ACID DERIVATIVES USEFUL AS ANTIBACTERIAL AGENTS | PFIZER INC. (US) | 2011-04-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120202777-A1 | C-Linked Hydroxamic Acid Derivatives Useful As Antibacterial Agents | HAX1, LPXN, AGXT | ACACB 565/4885LTA4H 115/4885PPARA 2041/4885 |
| US-20140364398-A1 | C-Linked Hydroxamic Acid Derivatives Useful As Antibacterial Agents | LCT, AGXT, PRXL2A | ACACB 178/4885LTA4H 352/4885PPARA 2068/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.